Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

With a much longer half-life than other radiotracers, flurpiridaz F-18 will boost patient access to PET imaging, one expert ...

While promising, questions remain about sustained long-term benefits of cardiac myosin inhibitors and their impact on ...

In one study, outcomes were similar regardless of baseline LVEF and recent worsening HF emerged as an important indicator.

Indications that the GLP-1 drug has greater benefits in the most frail patients should be viewed cautiously, one expert says.

Most of our top stories this month stemmed from the ESC Congress—a mix of drug and device trials as well as guidelines.

Among the trends in the report are a growing proportion of younger adults with HF and worsening of racial disparities.

The continuing rise in global stroke burden indicates that approaches to managing the problem need to change, including by ...

Cardia Ltd., a global leader in the development of leaflet modification solutions for treating heart valves, announced today that the United States Food and Drug Administration (FDA) provided market ...

The study reinforces the need to take the environment into account when focusing on CVD risk prevention, say experts.

Inspired by the drive and innovation within intervention, this fellow is also passionate about prevention.

Referrals to cardiac rehab are too rare and risk factor control is poor, with striking variation between sexes and among ...